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Abstract: Among women, the most prevalent type of cancer is breast cancer, affecting 1 out of every 8 women in the United States; 
in Puerto Rico, 70 out of every 100,000 will develop some type of breast cancer. Therefore, a better understand of the potential risk 
  factors for breast cancer could lead to the development of early detection tools. A gene that has been proposed as a risk factor in several 
populations around the world is Apolipoprotein E (apoE). ApoE functions as a mechanism of transport for lipoproteins and cholesterol 
throughout the body, with 3 main isoforms present in humans (apoE2, apoE3, and apoE4). Whether or not apoE4 is a risk factor for 
breast cancer remains controversial. Previous studies have either included test subjects of all ages (20–80) or have focused on late-onset 
(after age 50) breast cancer; none has concentrated specifically on early-onset (aged 50 and younger) breast cancer. The objectives of 
this study was to examine (in a Puerto Rican population) the differences in the relative frequency of occurrence of apoE4 in non-breast 
cancer versus breast cancer patients and to examine, as well, the potential differences of same in early- versus late-onset patients. We 
found an increased frequency of apoE4 (odds ratio 2.15) only in early-onset breast cancer survivors, which is similar to the findings of 
those studies that combined or adjusted for age as well as for an association between apoE4 and decreased tumor size. ApoE is also a 
potential risk factor for long-term cognitive effects after chemotherapy and affects response to hormone replacement. Our data supports 
the theory that knowing the apoE genotype of women who are at risk of developing breast cancer may be beneficial, as such knowledge 
would aid in the prediction of tumor size and the development of treatment regimens.
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cancer surveillance Report
Accounting for 20% of all malignancies in women 
(globally), breast carcinoma (BC) is the most com-
mon cancer to affect this population.1–3 The estimated 
annual  incidence  of  BC  worldwide  is  about  one 
  million cases.2,3 Studies conducted by the American 
Cancer  Society  indicate  that  there  are  2.5  million 
breast cancer survivors in the United States (2005), 
which  number  is  expected  to  increase  by  31%  by 
2015.2 This means that 1 out of every 8 women is 
expected to have some form of breast cancer in her 
lifetime.
Extensive research has been conducted in the last 
10  years  regarding  potential  genetic  risk  factors, 
one of those genes being apolipoprotein E (apoE).4–8 
The apoE gene is responsible for the metabolism of 
  lipoproteins and cholesterol as well as for the distri-
bution of these (metabolized) substances throughout 
the body.9 There are 3 main alleles found in humans, 
apoE2, apoE3, and apoE4. Changes in apoE4 allelic 
frequency are normally examined in association with 
the  increased  risk  of  age-related  cognitive  impair-
ments and the development of Alzheimer’s disease 
(AD), particularly in females.6–8 African Americans 
and Caribbean and Mexican Hispanics also display 
similar risk factors associated with the apoE4 allele, 
such as lowering the age of onset of sporadic AD 
and  reducing  memory  performance  in  individuals 
65 years and older.6–8 However, changes in apoE4 
allelic frequency are not limited to those with neu-
ronal conditions.
Various  investigations  also  indicate  that  apoE4 
allelic frequency is altered in various types of   cancer 
including  breast  cancer  and  early  onset  prostate 
cancer.6–8 The potential risk in the development of 
breast cancer and odds ratios appears to depend on 
the populations examined. In women from Turkey 
and Finland, either with or without breast cancer, no 
differences appear in apoE4 allelic frequency.6–8 In 
contrast, there are indications of an increase in apoE4 
allelic frequency in women from Taiwan, Italy, and 
Africa.6–8 One common limitation in most of the stud-
ies that hypothesize that apoE may be a potential risk 
factor in the development of breast cancer is that they 
did not include subjects who developed breast can-
cer at or before the age of 50.6–8 Studies that included 
young  subjects  with  early  onset  of  breast  cancer 
grouped  all  patients  together  or  adjusted  for  age 
(with ages   ranging from the 20s to the 80s).6–8 Those 
studies that used broad age ranges were more likely 
to report an association between being an apoE4 car-
rier and having a risk for breast cancer.6–8 Therefore, 
an explanation for the discrepancies that appear in 
the association of apoE4 and breast cancer risk is 
the  inclusion  of  early-onset  breast  cancer  patients. 
Understanding the genetics of early-onset breast can-
cer would increase the probability of early detection 
of tumors before the need for invasive treatments.
As of 2003, the incidence of women with breast can-
cer in Puerto Rico was 78 per 100,000, with 50.4 women 
per 100,000 receiving invasive treatment including 
surgery and/or chemotherapy.10–12 The mortality rate 
in 2003 was 16 per 100,000, resulting in approxi-
mately 1,540 deaths that year, making it the most 
prevalent, most commonly diagnosed cancer and the 
highest cause of cancer-related death among Puerto 
Rican women.12 The overall incidence of breast can-
cer is similar to levels reported in the United States 
(across all ages).12 However, the probability of Puerto 
Ricans developing the more advanced stage-4 can-
cers is 3.6 times higher, and Puerto Rican women 
have a 1.6 times greater risk of mortality compared 
to Hispanic whites.1 These rates are similar to other 
Hispanic  white  populations  including  Mexicans.1 
Breast Cancer is the most common form of cancer for 
Puerto Rican women, both for those residing on the 
island and for those in the mainland United States.13
In  regards  to  genetics,  Puerto  Ricans  and  other 
Caribbean Hispanics are very diverse and include His-
panic (European and South American), Caucasian, and 
African genes, along with other native groups. Stud-
ies involving the haplogroups of 800 mitochondrial 
DNAs (both randomly and systematically selected) 
suggest that the Puerto Rican population is genetically 
mixed, composed primarily of African, European and 
Amerindian  genes.14,15  This  population  represents 
individuals  affected  by  multiple  ancestral  genetic 
pools with implications that genetic risk factors are 
not specific to one ethnic group. The purpose of this 
study was to examine whether apoE allelic frequency 
was altered in Puerto Rican women and whether there 
were differences in the frequency with which this allele 
appeared  in  women  with  early-  onset  as  compared 
to those with late-onset breast cancer. Spreadsheets 
containing the obtained data were   converted and ana-
lyzed using SPSS 15.0 software.   Statistical differences Apoe risk early onset breast cancer
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between  groups  were  determined  by ANOVA,  the 
presence of apoE (apoE4 carrier vs. non-apoE4 car-
rier) and/or individuals diagnosed with breast cancer 
as the between-participant factors,   followed by Tukey-
Kramer post-hoc tests when appropriate. A Student’s 
t-test was used to analyze differences between non-
breast cancer and breast cancer subjects separated by 
age group (21–50, 51–89).
The collection of samples used in this study was 
approved by the IRB of the Ponce School of Medi-
cine, Ponce, PR, and participating hospitals for use in 
a large scale case-control study for which one of the 
co-authors (J.L.M.) is the PI. An informed consent 
was administered to each participant (cases and con-
trols) for interviewing, drawing blood samples and, 
for  cases,  obtaining  tumor  material  and  pathology 
reports. The design for this case-control study called 
for  utilizing  incident  cases;  it  began  with  recently 
diagnosed, histopathologically confirmed breast car-
cinoma cases. These recently diagnosed cases had not 
received  chemotherapy  and/or  radiotherapy.  These 
cases were recruited primarily through clinicians in the 
cities of Ponce, San Juan, and Yauco as well as other 
selected collaborating cities throughout Puerto Rico 
representing approximately 58 out of the 78 munici-
palities  (counties)  on  the  island.  Recruitment  sites 
included  the  Ponce  School  of  Medicine  Outpatient 
Clinic, Auxilio  Mutuo  Hospital  (San  Juan),  Damas 
Hospital  (Ponce)  and  St.  Luke’s  Hospital  (Ponce). 
Participants (cases and controls) were all of Hispanic 
origin.  An  epidemiological  questionnaire  soliciting 
information and variables that were related to breast 
carcinoma risk was provided to each participant. Only 
cases with primary and metastatic breast carcinoma 
tumors (rather than secondary or other types of cancer) 
were studied. The pathology report from each patient 
was obtained in order to learn the tumor grade, tumor 
size, and other clinically relevant information.
Controls were women who had never been diag-
nosed  with  breast  cancer  and  who  were  recruited 
consecutively from individuals visiting gynecologi-
cal and primary-care medical offices in Puerto Rico 
for their routine mammography and other types of 
screening. There was a possibility that controls would 
have more weight than cancer cases; that potential 
confounding factor as well as any other confound-
ing factors that became apparent were carefully ana-
lyzed and the properly adjustments made.16 Controls 
and cases were recruited from a population whose 
  members all visited the same sites (clinics, physicians’ 
offices, hospitals); any control who later developed 
breast cancer would be treated at the site from which 
she was recruited. Two main criteria determined the 
eligibility of controls: 1. any potential participant had 
to have had a normal clinical breast exam by her pri-
mary physician in the six months prior to enrollment, 
and 2. she had to have had a normal mammogram. 
These criteria reduced the likelihood of the existence 
of breast carcinoma among controls.
Approximately  thirty  milliliters  of  peripheral 
blood was obtained from each participant and stored 
in heparinized tubes. The lymphocytes were then iso-
lated by the Ficoll gradient technique and suspended 
in freezing media containing 10% dimethyl sulfoxide, 
40% RPMI-1640 medium, 50% fetal bovine serum, 
and  1%  antibiotic/antimycotic  the  resulting  solu-
tion was divided into 2.0 ml aliquots and stored in 
a freezer at -80 °C. These lymphocytes were later 
thawed in batches for DNA isolation. All of the sam-
ples came from Puerto Rican women, both with (205) 
and without (229) breast cancer, ranging in age from 
22 to 80 years old. Only those with available DNA as 
of August 2009 were used for this study. There was 
no overall difference or differences among #50 and 
51$ subjects with respect to age, family history of 
breast cancer, body mass index, whether they ever 
had been pregnant, or number of live births among 
age-matched groups (Table 1). This lack of associa-
tion between family history of breast cancer and age 
of onset has also been seen in other Hispanic popula-
tions.17 Civil status was the same among age-matched 
controls, though the older women were more likely to 
be widows (Table 1).
ApoE genotyping was performed by polymerase 
chain reaction with the BioRad DNA Engine Thermal 
Cycler from the Molecular Biology Core Laboratory. 
Approximately 200 ng of purified DNA was required 
for  a  high-quality  product.  Reactions  of  25  µL 
were  carried  with  a  PCR  Master  Mix  (Promega) 
Taq 50 U/mL, 400 µM of e/a dNTPs, and 3 mM 
MgCl2. The primers used were: (F4) 5'-ACAGAAT-
TCGCCCCGGCCTGGTACAC-3'  (1  mM)  and 
(F6)  5'-TAAGCTTGGCACGGCTGTCCAAGG-3’ 
(1  mM).18  Reactions  were  denatured  at  95 ° C  for 
5 min, followed by 35 cycles of primer annealing at 
60 °C for 1 min, extension at 70 °C for 2 min, and porrata-Doria et al
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denaturation at 95 °C for 1 min. This process was 
followed by a final extension of 10 min. After 3-hours 
of  digestion  with  CfoI/HhaI  (Promega),  products 
were run on 4% agarose gel, and bands were identi-
fied by size according to restriction fragment length 
polymorphism.19
The  frequency  of  overall  apoE4  carriers  within 
this population was 21.0% for women without breast 
cancer and 24.4% in breast cancer patients. There was 
no significant difference in frequency for any of the 
genotypes when grouping those with early-onset and 
late-onset breast cancer (p = 0.30) and those similar to 
excepted frequencies based on Caucasian   populations. 
However, with a 2 × 2 Analysis of   Variance (ANOVA), 
when comparing subjects that were diagnosed at or 
before the age of 50 versus those that were   diagnosed 
at  or  after  age  51  with  appropriate  controls,  we 
found a significant differences in genotype (F = 5.43, 
p , 0.02, Table 2). As seen in previous studies, in 
the late-onset breast cancer patients there were no dif-
ferences in apoE allelic frequency.4,5 In contrast, we 
found twice as many apoE3/apoE4 alleles in women 
who were 50 or younger, with a significant difference 
in those who are apoE carriers (F = 4.00, p , 0.05, 
Table 2), and no change in the frequency with which 
the apoE2/apoE3 genotype is found. The odds ratio 
for the frequency of apoE4 in women 50 and under 
between non-breast cancer and breast cancer patient’s 
was  2.15  (CI:  1.05–4.39).  The  apoE4  frequencies 
found in our population of early-onset individuals are 
Table 1. Demographics of non-breast cancer and breast cancer patients.
non-breast  
cancer  
(22–50 yrs)
Breast cancer 
(22–50 yrs)
p-value non-breast  
cancer  
(51–89 yrs)
Breast cancer 
(51–89 yrs)
p-value
Age ± S.e.M. (n) 41.7 ± 0.6 (106) 43.0 ± 0.6 (63) 0.38 61.8 ± 0.8 (123) 63.8 ± 0.7 (142) 0.06
% Family history  
of breast cancer (n)
49.0 ± 0.1 (98) 42.6 ± 0.1 (61) 0.51 40.3 ± 0.05 (119) 34.5 ± 0.04 (139) 0.36
Body mass index (n) 26.5 ± 0.5 (104) 26.6 ± 0.6 (63) 0.89 27.9 ± 0.4 (123) 27.8 ± 0.5 (142) 0.86
% ever been  
pregnant (n)
22.6 ± 0.05 (104) 25.4 ± 0.05 (63) 0.68 17.9 ± 0.03 (123) 18.3 ± 0.03 (142) 0.92
# Live births (n) 2.0 ± 0.1 (91) 2.3 ± 0.2 (55) 0.36 3.1 ± 0.2 (110) 2.8 ± 0.1 (125) 0.20
% Smoke (n) 11.6 ± 0.03 (103) 14.2 ± 0.04 (63) 0.63 12.5 ± 0.03 (120) 15.6 ± 0.03 (141) 0.47
% Alcohol (n) 37.6 ± 0.2 (93) 45.7 ± 0.2 (56) 0.79 43.7 ± 0.2 (112) 15.6 ± 0.03 (134) 0.25
Civil status (n) 105 63 122 142
  Married 67.4% 68.5% 65.5% 44.9%
  Single 22.0% 13.7% 13.8% 25.7%
  Divorced 9.6% 13.7% 17.2% 16.2%
  Widow 1.0% 4.0% 3.4% 13.2%
Table 2. Frequency of apoe genotypes in non-breast cancer and breast cancer patients.
non-breast cancer 
(21–50 yrs)
Breast cancer 
(21–50 yrs)1,2
non-breast cancer 
(51–89 yrs)
Breast cancer 
(51–89 yrs)
n 106 63 123 142
apoe2/apoe2 0 0 0 0
apoe2/apoe3 10.4%  7.9% 6.5% 5.7%
apoe3/apoe3 74.0%  58.7% 70.7% 74.6%
apoe3/apoe4 14.4%  33.3% 22.0% 17.6%
apoe2/apoe4 1.9%  0 0 0
apoe4/apoe4 0.9%  0 0.8% 2.1%
Non-apoe4 carrier 81.1%  66.7% 77.2% 79.6%
apoe4 carrier 18.9%  33.3% 22.8% 20.4%
1Significant difference in allelic frequency (P , 0.02). 
2Significant difference in frequency of apoE4 carriers (P , 0.05).Apoe risk early onset breast cancer
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the same as others found in an age-adjusted breast 
cancer population.20 We also found that apoE4 was 
associated  with  decreased  tumor  size  in  younger 
women, but not with tumor grade (Table 3). As other 
studies have made 51 (as opposed to 50) the cut-
off age for comparisons,21 we repeated analysis and 
found the same significant effect (decreased tumor 
size) in early-onset breast cancer patients in terms of 
apoE genotype (F = 4.76, p , 0.03) and apoE4 allelic 
frequency (F = 3.95, p , 0.05). These data suggest 
that apoE4 may be a risk factor for the early onset of 
breast cancer and affect tumor size in Puerto Rican 
women who have breast cancer.
Particular genes like apoE also affect the response 
to  chemotherapy  and  needed  hormone  treatment, 
which is an important factor to consider in the treat-
ment  of  breast  cancer.  In  Greek  post-menopausal 
women, apoE4 carriers displayed reduced response 
to  Tamoxifen.22  Research  suggests  that  knowing 
whether or not a patient’s gene profile includes the 
apoE polymorphism is critical when pondering the 
risks  and  benefits  of  using  estrogen  in  hormone 
therapy.23,24 Studies on apoE as a potential genetic 
risk factor in breast cancer or lymphoma survivors 
found  that  even  eight  years  after  chemotherapy, 
apoE4  carriers  displayed  impairments  specifically 
in visual memory, spatial ability, and psychomotor 
functioning.25
The current study suggests the importance of age of 
diagnosis as a factor in the relationship between apoE 
genotype and the risk for breast cancer. This study 
will need to be confirmed with additional ethnic/racial 
populations.  Nonetheless,  these  findings  suggest  a 
strong association between apoE genotype and age of 
diagnosis of breast cancer in Puerto Rican women. 
There  is  a  controversy  concerning  when  women 
should  start  getting  mammograms;  such  tests  are 
currently recommended for women between 45 and 
50 years of age, depending on case and family history. 
This might turn out to be too late for some women, 
considering the fact that the highest incidence rate for 
ethnic minorities is age 50 and below and that those 
with early onset are likely to have more aggressive 
disease.26 Our data indicates that studies on genetic 
markers  in  early-onset  breast  cancer  patients  may 
encourage women to rethink when they should start 
getting  mammograms  or  other  types  of  screening 
procedures.27,28
Knowing  an  individuals  apoE  genotype  would 
allow  the  physician  more  information  on  how  a 
patient may response to hormones and chemother-
apy if they are diagnosed. Taken together with past 
microarray  analyses  of  single  nucleotide  polymor-
phisms in middle European white women,23 our study 
supports the idea that breast cancer patients would 
benefit from health care professionals having access 
to their genetic profiles; such knowledge would aid in 
the design of treatment regimens as well as improve 
the effectiveness of genetic counseling.
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